Antibody Drug Conjugate News and Research

RSS

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2020 - forecasts the breast cancer treatment market to increase in value from $9.2 billion in 2013 to more than $13.1 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.1%.

24 Jun 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform...

9 Apr 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

Collaboration classification useful for Japanese lung cancer patients

Epidermal growth factor receptor status and prognosis in Japanese patients can be predicted by a recently developed lung adenocarcinoma classification system, say researchers.

23 Jul 2014

Apparent diffusion coefficient does not reflect cytotoxicedema on uninjured side after TBI

It is currently difficult to treat traumatic brain injury (TBI) in the clinic. There are abundant neural network connections and humoral regulation mechanisms between the cerebral hemispheres.

15 Jul 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

PolyTherics Limited, a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge antibody drug conjugate ("ADC") collaboration with MacroGenics Inc, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.

11 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Synthon’s SYD985 ADC demonstrates anti-tumor activity, outperforms leading anti-HER2 ADC

Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche's market leading anti-HER2 ADC, T-DM1 (Kadcyla).

2 Apr 2014

Omnicell’s Pandora business analytics solutions now available in the Middle East markets

Omnicell, Inc. (OMCL) today announced that its Pandora® business analytics solutions are now available for customers in the Middle East markets.

From Omnicell, Inc. 27 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

ADC values and diffusion weighted imaging can be used to detect early cerebral infarction

Supratentorial cerebral infarction can cause functional inhibition of remote regions such as the cerebellum, which may be relevant to diaschisis. This phenomenon is often analyzed using positron emission tomography and single photon emission CT. However, these methods are expensive and radioactive.

6 Jan 2014

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013